Celltrion is set to introduce clinical data for its allergy treatment “Omlyclo” (development name CT-P39) to local healthcare professionals ahead of its launch in Japan. After obtaining marketing approval in Japan in March and completing reimbursement listing, the company is preparing for sales and plans to promote product information through an international academic conference.

Celltrion announced on the 13th that it will participate in the World Allergy Congress (WAC 2026), to be held from the 15th to the 18th of this month at the Kyoto International Conference Center in Japan.

Omlyclo is a biosimilar of omalizumab and will be marketed in Japan under the product name “Omalizumab BS CT.” In March, it received marketing approval in Japan with indications for bronchial asthma, chronic spontaneous urticaria, and seasonal allergic rhinitis. It subsequently went through the reimbursement listing process and is currently being prepared for launch in Japan as the world’s first omalizumab biosimilar. The specific sales start date has not been disclosed.

This congress is co-hosted by the World Allergy Organization (WAO), the Japanese Society of Allergology (JSA), and the Asia Pacific Association of Pediatric Allergy, Respirology and Immunology (APAPARI). Approximately 7,000 medical experts in allergy, respiratory, and immunology from around the world are expected to attend.

During the congress, Celltrion will operate a corporate booth and present Omlyclo’s clinical data as well as information related to production and supply. On the 16th, it will hold a seminar for about 400 healthcare professionals under the theme “Expanding Treatment Options Through Biosimilars.” Professor Emeritus Kimihiro Okubo of Nippon Medical School will serve as chair of the panel discussion.

Celltrion plans to leverage its existing sales network in Japan for the launch of Omlyclo. According to pharmaceutical market research firm IQVIA, as of July this year Celltrion’s market share in Japan was 48% for Remsima, 21% for Yuflyma, 78% for Herzuma, and 64% for Vegzelma.

Omlyclo was first launched in Europe in September last year and recorded a 21% market share in Europe as of the first quarter of this year. Its global sales in the first half of this year amounted to KRW 188.4 billion. On the 5th of this month, it also became the first omalizumab biosimilar to start sales in the United States.

A Celltrion official said, “Based on the direct sales infrastructure established in Japan by products such as Remsima and Herzuma, the company plans to work to ensure that Omlyclo also secures a solid position in the Japanese allergy treatment market.”

Popular News